MOTIF BIO PLC/S - MTFB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.11
+0 (0.00%)
Get New MOTIF BIO PLC/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTFB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTFB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MOTIF BIO PLC/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.11.

This chart shows the closing price for MTFB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in MOTIF BIO PLC/S. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2019Northland SecuritiesSet TargetBuy$5.00High
3/26/2019Northland SecuritiesReiterated RatingBuy$5.00Low
2/25/2019HC WainwrightDowngradeBuy ➝ NeutralLow
10/9/2018HC WainwrightSet TargetBuy$32.00High
8/14/2018HC WainwrightSet TargetBuy$32.00High
8/8/2018HC WainwrightSet TargetBuy$32.00Low
6/11/2018HC WainwrightReiterated RatingBuy$32.00High
4/19/2018HC WainwrightReiterated RatingBuy$32.00High
4/16/2018Northland SecuritiesInitiated CoverageOutperformLow
3/29/2018GabelliReiterated RatingHoldHigh
12/29/2017WBB SecuritiesInitiated CoverageSell$7.00Low
10/11/2017HC WainwrightSet TargetBuy$32.00N/A
10/4/2017HC WainwrightBoost TargetBuy$25.00 ➝ $32.00High
9/20/2017HC WainwrightReiterated RatingBuy$25.00High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
MOTIF BIO PLC/S logo
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.11
Low: $0.10
High: $0.12

50 Day Range

MA: $0.10
Low: $0.10
High: $0.11

52 Week Range

Now: $0.11
Low: $0.08
High: $11.50

Volume

867,698 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MOTIF BIO PLC/S?

The following Wall Street analysts have issued research reports on MOTIF BIO PLC/S in the last twelve months:
View the latest analyst ratings for MTFB.

What is the current price target for MOTIF BIO PLC/S?

0 Wall Street analysts have set twelve-month price targets for MOTIF BIO PLC/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MOTIF BIO PLC/S in the next year.
View the latest price targets for MTFB.

What is the current consensus analyst rating for MOTIF BIO PLC/S?

MOTIF BIO PLC/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MTFB.

What other companies compete with MOTIF BIO PLC/S?

How do I contact MOTIF BIO PLC/S's investor relations team?

MOTIF BIO PLC/S's physical mailing address is 201 TEMPLE CHAMBERS 3-7 TEMPLE AVENUE, LONDON X0, EC4Y0DT. The company's listed phone number is 212-210-6248 and its investor relations email address is [email protected] The official website for MOTIF BIO PLC/S is www.motifbio.com. Learn More about contacing MOTIF BIO PLC/S investor relations.